Merck & Co., Inc. (MRK)
| Market Cap | 200.53B |
| Revenue (ttm) | 63.62B |
| Net Income (ttm) | 16.41B |
| Shares Out | 2.51B |
| EPS (ttm) | 6.49 |
| PE Ratio | 12.31 |
| Forward PE | 8.72 |
| Dividend | $3.24 (4.06%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 13,380,887 |
| Open | 79.06 |
| Previous Close | 79.29 |
| Day's Range | 78.43 - 79.99 |
| 52-Week Range | 73.31 - 120.30 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 111.14 (+39.17%) |
| Earnings Date | Jul 29, 2025 |
About ENV
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $111.14, which is an increase of 39.17% from the latest price.
News
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
Top 10 High-Yield Dividend Stocks For August 2025
My watchlist aims to identify high-quality, high-yield stocks trading at attractive valuations, outperforming benchmarks in yield, and offering strong long-term CAGR. The August 2025 Top 10 list remai...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
European drugmakers fall after Trump raises stakes over US drug price cuts
Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping ex...
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
Merck Stock Is Almost A Classical Benjamin Graham Investment
Merck is good value for money. It is a highly profitable company. It fulfills almost all of Benjamin Graham's stock-picking criteria.
Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Caroline A. Litchfield - Executive VP & CFO Dean Y.
'Halftime' Committee Stocks on the Move: UnitedHealth, Merck, Royal Caribbean and Spotify
The Investment Committee debate some of their stocks on the move lower.
Merck will lay off employees and shed some real estate to cut $3 billion in costs
Merck's stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include layoffs.
Merck plans $3 billion cost cuts by end of 2027 - narrows full-year outlook
CNBC's Joe Kernen reports on the company's quarterly earnings results.
Merck to Lay Off Workers and Narrows Guidance as Earnings Fall
Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, as it looks to redirect resources toward new product launches.
Merck to cut jobs and costs as demand for Gardasil in China remains weak
Drugmaker Merck & Co on Tuesday announced job and cost cuts it said will save $3 billion a year as it posted lower second-quarter results due to continuing weak demand for its Gardasil vaccine in Chin...
Merck plans $3 billion cost cuts by end of 2027 narrows full-year outlook
Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline. The multi-year effort comes as Merck prepares ...
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results.
Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector
Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.
How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings
Merck & Co., Inc. MRK will release earnings results for the second quarter before the opening bell on Tuesday, July 29.
Sell Merck Stock Ahead Of Its Upcoming Earnings?
Merck (NYSE:MRK) is set to reveal its earnings on Tuesday, July 29, 2025. Historically, MRK stock has exhibited a trend of negative one-day returns following earnings announcements.
U.S. Keytruda Market Research Report 2025 | Merck's Keytruda Faces Challenges as Patent Expiry Approaches in 2028 - Forecast to 2033
The U.S. Keytruda market, valued at $17.87 billion in 2024, faces a projected CAGR decline of -3.12% by 2033 due to patent expiration and biosimilar competition. Keytruda's continued use in various ca...
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...